Ajanta Pharma Launches Met-XL D to Improve Outcomes for Heart Failure and Post-Myocardial Infarction Patients

Ajanta Pharma, one of the leaders in the cardiology segment has
launched the fixed dose combination of Metoprolol and Dapagliflozin under the
brand name Met XL D. Met XL D
is indicated for patients with heart failure, post myocardial infarction, and
individuals at high cardiovascular disease risk.

Met
XL D is a fixed-dose combination tablet of Metoprolol Extended Release, a
beta-blocker, and Dapagliflozin, an SGLT2 inhibitor. It is available in two
dosage strengths and contains Metoprolol 25 mg with Dapagliflozin 10 mg, or
Metoprolol 50 mg with Dapagliflozin 10 mg.

The
American College of Cardiology guidelines mention a
Class 1a recommendation for beta-blockers and SGLT2 inhibitors in heart failure
with reduced ejection fraction (HFrEF) to reduce mortality and
hospitalizations. The European Society of
Cardiology guidelines suggest a Class 1a recommendation for SGLT2 inhibitors
and a Class 2b recommendation for beta-blockers in heart failure with mildly
reduced ejection fraction (HFmrEF).

With 24-hour blood pressure control and reduced pill burden, this combination therapy is
designed to improve the clinical status, functional capacity, and quality of
life among heart failure patients.

Speaking
to Medical Dialogues Mr. Pourus Vakil, President & India Business Head,
from Ajanta Pharma said “At Ajanta Pharma, we are committed to advancing
cardiovascular disease care through innovative therapeutic solutions. The dual
action of metoprolol and dapagliflozin provides comprehensive care, reducing
hospitalization, improving heart function and ultimately saving lives. Aligned
with the latest clinical guidelines, we aim to
improve clinical outcomes and quality of life in
high-risk patients.”